The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.
Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
-
Idiopathic Pulmonary Fibrosis companies working in the treatment market are FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment
-
Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
-
In September 2024, Insilico Medicine has reported encouraging preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug developed using generative AI for the treatment of idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled trial was conducted at 21 sites in China, enrolling 71 patients with IPF. It evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12 weeks of oral ISM001-055. The study included four groups: a placebo group, and three treatment groups receiving 30 mg once daily (QD), 30 mg twice daily (BID), and 60 mg QD.
-
In July 2024, South Korean biotechnology company Bridge Biotherapeutics has completed enrollment for its Phase II clinical trial of BBT-877, a novel autotaxin inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).
-
In May 2024, Aileron Therapeutics has announced positive results from the first cohort of its ongoing Phase Ib clinical trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled, multicenter dose-escalation study includes recently diagnosed IPF patients who have not received anti-fibrotic treatment for at least two months.
-
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2b CORAL clinical trial, which will evaluate three doses of Haduvio™ (oral nalbuphine ER) in comparison to a placebo in around 160 idiopathic pulmonary fibrosis (IPF) patients with chronic cough. This Phase 2b trial builds on the success of the Phase 2a CANAL trial, which showed a 75.1% reduction in daytime cough frequency, representing a 52.5% improvement over placebo (p<0.0001). Haduvio is also being developed for refractory chronic cough (RCC) and prurigo nodularis.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring (fibrosis) of the lung tissue. In IPF, the lung tissue becomes thickened, stiff, and scarred over time, making it difficult for the lungs to function properly and limiting the ability to breathe.
Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight
Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
-
Pamrevlumab: FibroGen
-
Tipelukast: MediciNova
-
PLN-74809: Pliant Therapeutics
-
HZN-825: Horizon Pharmaceuticals
-
Brilaroxazine: Reviva Pharmaceuticals
-
PRM-151: Roche
-
C21: Vicore Pharma
-
TXR 1002: Aria Pharmaceuticals
-
INS018_055: InSilico Medicine
-
AD-214: AdAlta
-
AZD5055: AstraZeneca
-
LTI-03: Lung Therapeutics
-
CSL312: CSL Behring
-
GB0139: Galecto Biotech AB
-
PLN-74809: Pliant Therapeutics
-
ENV-101: Endeavor BioMedicine
-
Pamrevlumab: FibroGen
-
BI-1015550: Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis Route of Administration
Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Idiopathic Pulmonary Fibrosis Molecule Type
Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
-
Idiopathic Pulmonary Fibrosis Assessment by Product Type
-
Idiopathic Pulmonary Fibrosis By Stage and Product Type
-
Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
-
Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
-
Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
-
Idiopathic Pulmonary Fibrosis by Stage and Molecule Type
DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies
Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:
Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., Jubliant Pharma Limited (Jubliant Cadista Limited), Merck & Co. Inc., United Therapeutics, Boehringer Ingelheim International GmbH, Horizon Therapeutics Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others.
Idiopathic Pulmonary Fibrosis Pipeline Analysis:
The Idiopathic Pulmonary Fibrosis pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
-
Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies
Idiopathic Pulmonary Fibrosis Pipeline Market Drivers
-
Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.
Idiopathic Pulmonary Fibrosis Pipeline Market Barriers
-
However, Lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of IPF is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis (IPF) and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.
Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
-
Coverage: Global
-
Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
-
Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
-
Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
-
Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers
Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials
Table of Contents
1. Idiopathic Pulmonary Fibrosis Report Introduction
2. Idiopathic Pulmonary Fibrosis Executive Summary
3. Idiopathic Pulmonary Fibrosis Overview
4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)
7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)
8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)
9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products
10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment
11. Idiopathic Pulmonary Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Idiopathic Pulmonary Fibrosis Key Companies
14. Idiopathic Pulmonary Fibrosis Key Products
15. Idiopathic Pulmonary Fibrosis Unmet Needs
16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers
17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion
18. Idiopathic Pulmonary Fibrosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/